ASX:PAR

Paradigm Biopharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.81 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive PAR News and Ratings via Email

Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Paradigm Biopharmaceuticals (ASX:PAR) Frequently Asked Questions

What stocks does MarketBeat like better than Paradigm Biopharmaceuticals?

Wall Street analysts have given Paradigm Biopharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Paradigm Biopharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Paradigm Biopharmaceuticals' key executives?

Paradigm Biopharmaceuticals' management team includes the following people:
  • Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC, CEO, MD & Exec. Chairman (Age 62, Pay $632.36k)
  • Mr. Justin Cahill, Chief Financial Officer
  • Dr. Jeannette Joughin, Chief Operating Officer
  • Dr. Ravi Krishnan, Chief Scientific Officer
  • Ms. Simon White, Director of Investor Relations
  • Dr. Michael Imperiale, Global Head of Safety
  • Dr. Donna L. Skerrett, Chief Medical Officer & Exec. Director (Age 64)
  • Ms. Beverley Huttmann, Commercial Head
  • Ms. Michelle Coffey, Global Head of Regulatory Affairs
  • Mr. Kevin G. Hollingsworth, Company Sec. (Age 68)

Who are some of Paradigm Biopharmaceuticals' key competitors?

What other stocks do shareholders of Paradigm Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), First Graphene (FGR), Envirosuite (EVS), Bubs Australia (BUB), Blue Energy (BLU), BHP Group (BHP), Alcidion Group (ALC), The a2 Milk (A2M) and 8common (8CO).

What is Paradigm Biopharmaceuticals' stock symbol?

Paradigm Biopharmaceuticals trades on the ASX under the ticker symbol "PAR."

How much money does Paradigm Biopharmaceuticals make?

Paradigm Biopharmaceuticals has a market capitalization of $0.00 and generates $20,550.00 in revenue each year.

How many employees does Paradigm Biopharmaceuticals have?

Paradigm Biopharmaceuticals employs 1,031 workers across the globe.

What is Paradigm Biopharmaceuticals' official website?

The official website for Paradigm Biopharmaceuticals is www.paradigmbiopharma.com.

Where are Paradigm Biopharmaceuticals' headquarters?

Paradigm Biopharmaceuticals is headquartered at Par Technology Park, New Hartford, New York 13413.

How can I contact Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals' mailing address is Par Technology Park, New Hartford, New York 13413. The company can be reached via phone at 61 3 9629 5566.


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.